Skip to ContentSkip to Navigation
How to find us prof. dr. M. (Michiel) Rienstra

Research interests

Graduated in medicine at the University of Antwerp, Belgium in 2003. Obtained a PhD at the University of Groningen, The Netherlands in 2007 on Atrial Fibrillation, Underlying Disease and Prognosis. I completed my cardiology training at the University Medical Center Groningen in 2012, where continued working as clinical cardiologist and researcher. I was awarded with a NWO Rubicon grant in 2009 and went to Harvard Medical School, Massachusetts General Hospital and the Framingham Heart Study for a post-doc on population genetics and epidemiology in 2010-2011. In 2012 I was awarded with the NWO Veni grant for his project on genetics of atrial fibrillation. In 2015 I received the European Society of Cardiology academic grant for his project on a big data approach in atrial fibrillation. I am work package leader of 4 large national consortia; RACE V (hypercoagulability and AF progression), RED-CVD (early detection of cardiovascular disease in general practices), AI (catalyzing the application of artificial intelligence in CV disease), and MyDigiTwin (Big-data and Artificial Intelligence-based ecosystem to create a user’s personal “Digital Twin”) . I am steering committee member of several investigator-initiated clinical studies (RACE 2 to 7, MARC 1-2, VIP-HF, DECISION). I am fellow of the European Society of Cardiology and the American Heart Association, and Scientific & Clinical Education Lifelong Learning Committee (SCILL) member of the AHA - Genomics and Precision Medicine council.


I combine clinical cardiology focusing on treatment of patients with arrhythmias, with clinical-oriented research. My research consists of conducting clinical studies to improve AF treatment, studying epidemiology of AF and its risk factors in PREVEND, Lifelines and Framingham Heart Study, uncovering the genetics of atrial fibrillation in part with the international AFGen onsortium, and applying novel bioinformatics tools to improve AF risk prediction.

Read more


Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective

Incidence and outcome of atrial fibrillation: diversity throughout Europe

Risk prediction of atrial fibrillation in the community combining biomarkers and genetics

Segment length in cine (SLICE) strain analysis: a practical approach to estimate potential benefit from cardiac resynchronization therapy

A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure Design and rationale of the MONITOR HF multicentre randomised clinical trial

Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop

Association between heart failure aetiology and magnitude of echocardiographic remodelling and outcome of cardiac resynchronization therapy

Atrial fibrillation in chronic heart failure patients with reduced ejection fraction: The CHECK-HF registry

Atrial fibrillation progression risk factors and associated cardiovascular outcome in well-phenotyped patients: data from the AF-RISK study

Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure

Read more


CONNECT magazine

Ik vertrouw op mijn collega's in de regionale ziekenhuizen

Dagblad van het Noorden interview; ‘Samen voor het hart‘

NFU Rapport “Onderzoek en innovatie met en voor de gezonde regio” aangeboden aan minister Bruins, VWS.

Read more